JP7525980B2 - 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法 - Google Patents

抗Ｓｉｇｌｅｃ－７抗体及びその使用方法 Download PDF

Info

Publication number
JP7525980B2
JP7525980B2 JP2018511133A JP2018511133A JP7525980B2 JP 7525980 B2 JP7525980 B2 JP 7525980B2 JP 2018511133 A JP2018511133 A JP 2018511133A JP 2018511133 A JP2018511133 A JP 2018511133A JP 7525980 B2 JP7525980 B2 JP 7525980B2
Authority
JP
Japan
Prior art keywords
siglec
amino acid
seq
hvr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018511133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525999A5 (enExample
JP2018525999A (ja
Inventor
ケイト モンロー，
ヘレン ラム，
アーノン ローゼンタール，
スンジュ リー，
フランチェスカ アヴォガドリ－コナーズ，
ウィリアム モンティース，
Original Assignee
アレクトル エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクトル エルエルシー filed Critical アレクトル エルエルシー
Publication of JP2018525999A publication Critical patent/JP2018525999A/ja
Publication of JP2018525999A5 publication Critical patent/JP2018525999A5/ja
Priority to JP2021167895A priority Critical patent/JP2022028653A/ja
Priority to JP2023158382A priority patent/JP2024009818A/ja
Application granted granted Critical
Publication of JP7525980B2 publication Critical patent/JP7525980B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2018511133A 2015-08-28 2016-08-26 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法 Active JP7525980B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021167895A JP2022028653A (ja) 2015-08-28 2021-10-13 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
JP2023158382A JP2024009818A (ja) 2015-08-28 2023-09-22 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562211656P 2015-08-28 2015-08-28
US62/211,656 2015-08-28
US201562265742P 2015-12-10 2015-12-10
US62/265,742 2015-12-10
PCT/US2016/049032 WO2017040301A1 (en) 2015-08-28 2016-08-26 Anti-siglec-7 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021167895A Division JP2022028653A (ja) 2015-08-28 2021-10-13 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2018525999A JP2018525999A (ja) 2018-09-13
JP2018525999A5 JP2018525999A5 (enExample) 2019-10-10
JP7525980B2 true JP7525980B2 (ja) 2024-07-31

Family

ID=56853902

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018511133A Active JP7525980B2 (ja) 2015-08-28 2016-08-26 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
JP2021167895A Pending JP2022028653A (ja) 2015-08-28 2021-10-13 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
JP2023158382A Pending JP2024009818A (ja) 2015-08-28 2023-09-22 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021167895A Pending JP2022028653A (ja) 2015-08-28 2021-10-13 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
JP2023158382A Pending JP2024009818A (ja) 2015-08-28 2023-09-22 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法

Country Status (9)

Country Link
US (3) US10590198B2 (enExample)
EP (1) EP3341411B1 (enExample)
JP (3) JP7525980B2 (enExample)
KR (1) KR20180054639A (enExample)
CN (2) CN115960235A (enExample)
AU (1) AU2016316768A1 (enExample)
CA (1) CA2996059A1 (enExample)
HK (1) HK1252696A1 (enExample)
WO (1) WO2017040301A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
ES3040431T3 (en) 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
JP7525980B2 (ja) * 2015-08-28 2024-07-31 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
EP3402516A4 (en) * 2016-01-12 2020-01-08 Palleon Pharmaceuticals Inc. USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER
US11773162B2 (en) 2016-08-05 2023-10-03 Allakos, Inc. Anti-Siglec-7 antibodies for the treatment of cancer
KR20250158824A (ko) * 2016-09-10 2025-11-06 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질병 또는 손상의 치료를 위한 전신 조절 t 세포 수준 또는 활성 감소
BR112019018429A2 (pt) * 2017-03-06 2020-04-14 Univ Pennsylvania anticorpo, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indíviduo e para reduzir a atividade de um sistema complemento de um indivíduo, e, célula
CN113336849A (zh) * 2017-03-28 2021-09-03 礼进生物医药科技（上海）有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US20200132691A1 (en) * 2017-04-24 2020-04-30 The General Hospital Corporation Detection and targeting of tumor-promoting neutrophils
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
EP3737410A4 (en) * 2018-01-11 2022-04-20 Allakos, Inc. Anti-siglec-7 antibodies having reduced effector function
US20210395333A1 (en) * 2018-06-07 2021-12-23 Palleon Pharmaceuticals Inc. Multimeric proteins for detecting a carbohydrate and/or treating a siglec-mediated disorder
CN119841953A (zh) 2018-06-08 2025-04-18 艾利妥 抗siglec-7抗体及其使用方法
US12060422B2 (en) * 2018-06-29 2024-08-13 Alector Llc Anti-SIRP-Beta1 antibodies and methods of use thereof
SG11202100555PA (en) 2018-07-27 2021-02-25 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
JP7653909B2 (ja) 2018-09-06 2025-03-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒト化抗ｃ５抗体とその利用
CA3145885A1 (en) * 2019-07-31 2021-02-04 Jeonghoon Sun Anti-ms4a4a antibodies and methods of use thereof
CN111647084B (zh) * 2020-06-13 2020-12-01 广东赛尔生物科技有限公司 抗c-MET抗体及其在治疗癌症中的应用
CA3183994A1 (en) 2020-06-24 2021-12-30 Philip James Dolan Iii Antibodies recognizing sortilin
CN112877394A (zh) * 2021-01-27 2021-06-01 南京大学 B7-h4+单核细胞型mdsc在制备ins激素治疗疗效预测试剂中的应用
IL313812A (en) * 2021-12-23 2024-08-01 Prothena Biosciences Ltd Antibodies that recognize SORTILIN
JP2025511188A (ja) * 2022-03-31 2025-04-15 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー ヒトＳｉｇｌｅｃ－７に対する抗体及び免疫療法のためのその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003517482A (ja) 1999-12-16 2003-05-27 ウニベルシタ デリィ ストゥディ ディ ジェノバ，ディパルティメント ディ メディチナ スペリメンターレ ｐ７５／ＡＩＲＭ１の結合による診断及び治療法

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
JPH06500011A (ja) 1990-06-29 1994-01-06 ラージ　スケール　バイオロジー　コーポレイション 形質転換された微生物によるメラニンの製造
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1994002499A1 (en) 1992-07-27 1994-02-03 Hybridon, Inc. Oligonucleotide alkylphosphonothioates
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
CA2154358A1 (en) 1993-01-21 1994-08-04 Hybridon, Inc. Integrated oligonucleotides
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5962674A (en) 1995-06-01 1999-10-05 Hybridon, Inc. Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages
US6140482A (en) 1995-06-01 2000-10-31 Hybridon, Inc. Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same
US5955599A (en) 1995-06-01 1999-09-21 Hybridon, Inc. Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages
US5614622A (en) 1995-06-01 1997-03-25 Hybridon, Inc. 5-pentenoyl moiety as a nucleoside-amino protecting group, 4-pentenoyl-protected nucleotide synthons, and related oligonucleotide syntheses
US5637683A (en) 1995-07-13 1997-06-10 Cornell Research Foundation, Inc. Nucleic acid analog with amide linkage and method of making that analog
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US6117992A (en) 1996-08-26 2000-09-12 Hybridon, Inc. Reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages
US5886165A (en) 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US5739314A (en) 1997-04-25 1998-04-14 Hybridon, Inc. Method for synthesizing 2'-O-substituted pyrimidine nucleosides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2000056746A2 (en) 1999-03-24 2000-09-28 Exiqon A/S Improved synthesis of [2.2.1]bicyclo nucleosides
KR20010001577A (ko) 1999-06-07 2001-01-05 윤종용 고분자 광산발생제를 이용한 올리고펩티드 핵산 탐침의 제조방법
AU6629200A (en) 1999-08-25 2001-03-19 Philip P Garner Alpha-helical peptide nucleic acid alpha-pna
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
JP2003520828A (ja) * 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
AU2001274939A1 (en) * 2000-05-24 2001-12-03 Smith Kline Beecham Corporation Sialoadhesin factor-3 antibodies
US6455308B1 (en) 2001-08-01 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of serum amyloid A4 expression
JP2006504971A (ja) 2002-11-01 2006-02-09 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト マトリックス支援レーザー脱離イオン化−飛行時間型質量分析によるタンパク質アイソフォームの定量的解析
CA2882022A1 (en) * 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
KR20070107687A (ko) 2004-12-31 2007-11-07 제넨테크, 인크. Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
MX2010007935A (es) * 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
AR075989A1 (es) * 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
EP3187877A1 (en) 2009-09-25 2017-07-05 XOMA Technology Ltd. Screening methods
WO2012009568A2 (en) 2010-07-16 2012-01-19 Adimab, Llc Antibody libraries
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US9175092B2 (en) * 2011-06-28 2015-11-03 Oxford Biotherapeutics Ltd Antibodies to bone marrow stromal antigen 1
DK2935330T3 (da) * 2012-12-19 2019-07-22 Aveo Pharmaceuticals Inc Anti-notch3-antistoffer
EP2970435B1 (en) * 2013-03-15 2020-08-12 Eli Lilly and Company Methods for producing fabs and bi-specific antibodies
TW201722994A (zh) * 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
JP2017500028A (ja) * 2013-12-12 2017-01-05 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗ｄｐｅｐ３抗体および使用方法
WO2016038064A1 (en) 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies
CA2976926A1 (en) * 2015-02-19 2016-08-25 Compugen Ltd. Anti-pvrig antibodies and methods of use
JP7525980B2 (ja) 2015-08-28 2024-07-31 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
US11459398B2 (en) 2016-07-01 2022-10-04 The Board Of Trustees Of The Leland Stanford Junior University Conjugates for targeted cell surface editing
CN106831989A (zh) 2017-01-04 2017-06-13 中国人民解放军南京军区军事医学研究所 人源抗唾液酸结合免疫球蛋白样凝集素‑7的抗体IgG及其应用
EP3737410A4 (en) 2018-01-11 2022-04-20 Allakos, Inc. Anti-siglec-7 antibodies having reduced effector function
CN119841953A (zh) 2018-06-08 2025-04-18 艾利妥 抗siglec-7抗体及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003517482A (ja) 1999-12-16 2003-05-27 ウニベルシタ デリィ ストゥディ ディ ジェノバ，ディパルティメント ディ メディチナ スペリメンターレ ｐ７５／ＡＩＲＭ１の結合による診断及び治療法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｓ Ｊ ＯＲＲ，ＳＯＣＳ３ ＴＡＲＧＥＴＳ ＳＩＧＬＥＣ ７ ＦＯＲ ＰＲＯＴＥＡＳＯＭＡＬ ＤＥＧＲＡＤＡＴＩＯＮ ＡＮＤ ＢＬＯＣＫ ＳＩＧＬＥＣ ７－ＭＥＤＩＡＴＥＤ ＲＥＳＰＯＮＳＥＳ，ＪＯＵＲＮＡＬ ＯＦ ＢＩＯＬＯＧＩＣＡＬ ＣＨＥＭＩＳＴＲＹ，米国，２００６年 ８月１４日，Ｖ２８２ Ｎ６，Ｐ３４１８－３４２２，ＵＲＬ，ｈｔｔｐ：／／ｄｘ．ｄｏｉ．ｏｒｇ／１０．１０７４／ｊｂｃ．Ｃ６００２１６２００
ＳＴＥＦＡＮＩＡ ＶＡＲＣＨＥＴＴＡ，ＳＩＡＬＩＣ ＡＣＩＤ－ＢＩＮＤＩＮＧ ＩＧ－ＬＩＫＥ ＬＥＣＴＩＮ－７ ＩＮＴＥＲＡＣＴＳ ＷＩＴＨ ＨＩＶ－１ ＧＰ１２０ ＡＮＤ ＦＡＣＩＬＩＴＡＴＥＳ ＩＮＦＥＣＴＩＯＮ 以下備考，ＲＥＴＲＯＶＩＲＯＬＯＧＹ，英国，ＢＩＯＭＥＤ ＣＥＮＴＲＡＬ ＬＴＤ，２０１３年１２月１３日，ＶＯＬ：１０， ＮＲ：１，，ＰＡＧＥ（Ｓ）：１５４／１－１３，ＯＦ ＣＤ４ＰＯＳ Ｔ ＣＥＬＬＳ ＡＮＤ ＭＡＣＲＯＰＨＡＧＥＳ，ＵＲＬ，ｈｔｔｐ：／／ｄｘ．ｄｏｉ．ｏｒｇ／１０．１１８６／１７４２－４６９０－１０－１５４

Also Published As

Publication number Publication date
JP2022028653A (ja) 2022-02-16
US10590198B2 (en) 2020-03-17
KR20180054639A (ko) 2018-05-24
EP3341411A1 (en) 2018-07-04
CN115960235A (zh) 2023-04-14
CN108137702A (zh) 2018-06-08
US20180244770A1 (en) 2018-08-30
AU2016316768A1 (en) 2018-03-29
EP3341411B1 (en) 2025-06-11
WO2017040301A1 (en) 2017-03-09
JP2018525999A (ja) 2018-09-13
CA2996059A1 (en) 2017-03-09
US20220411503A1 (en) 2022-12-29
HK1252696A1 (zh) 2019-05-31
JP2024009818A (ja) 2024-01-23
US20200277374A1 (en) 2020-09-03
CN108137702B (zh) 2023-01-06
US11390680B2 (en) 2022-07-19

Similar Documents

Publication Publication Date Title
US20220411503A1 (en) Anti-siglec-7 antibodies and methods of use thereof
US11667710B2 (en) Anti-Siglec-9 antibodies and methods of use thereof
US20220281976A1 (en) Anti-cd33 antibodies and methods of use thereof
US20220251190A1 (en) Anti-cd33 antibodies and methods of use thereof
US11965023B2 (en) Anti-Siglec-5 antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211013

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220531

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220614

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220712

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220719

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220902

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240719

R150 Certificate of patent or registration of utility model

Ref document number: 7525980

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150